Adherence to suppression therapy guidelines after thyroid cancer surgery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928867" target="_blank" >RIV/00064173:_____/25:43928867 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43928867 RIV/00216208:11130/25:10503594

Výsledek na webu

<a href="https://doi.org/10.1007/s44411-025-00377-1" target="_blank" >https://doi.org/10.1007/s44411-025-00377-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s44411-025-00377-1" target="_blank" >10.1007/s44411-025-00377-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Adherence to suppression therapy guidelines after thyroid cancer surgery

Popis výsledku v původním jazyce

Objective: Thyroid-stimulating hormone (TSH) suppression therapy with levothyroxine is essential for patients with differentiated thyroid cancer (DTC) after surgery. While it reduces recurrence risk in high-risk patients, its intensity should be tailored according to risk stratification. This study aimed to evaluate physicians&apos; adherence to recommendations on TSH suppression therapy in patients with DTC after surgery and/or radioiodine therapy. Design: This prospective study included patients managed at two specialized centres following total thyroidectomy for DTC. Methods: Patients on a stable levothyroxine dose for at least three months were enrolled. Data collected at the last follow-up included serum TSH, free thyroxine (FT4), free triiodothyronine (FT3), thyroglobulin, and anti-thyroglobulin antibody levels. TSH values were categorized as within target range, below target (over-suppressed), or above target (under-suppressed) according to American Thyroid Association guidelines and recurrence risk (low, intermediate, high). Results: Of 365 patients (female/male ratio: 306/59; mean age: 54.7 years for females, 56.3 years for males), only 136 (37.3%) achieved target TSH levels. TSH was under-suppressed in 86 patients (23.6%) and over-suppressed in 129 patients (35.3%). Over-suppression was most prevalent (62%) in the low-risk group. Conclusions: Adherence to guideline-recommended TSH suppression therapy in DTC remains suboptimal, with frequent over-suppression, particularly in low-risk patients. These findings highlight the need for individualized suppression strategies balancing recurrence prevention and the avoidance of iatrogenic complications.

Název v anglickém jazyce

Adherence to suppression therapy guidelines after thyroid cancer surgery

Popis výsledku anglicky

Objective: Thyroid-stimulating hormone (TSH) suppression therapy with levothyroxine is essential for patients with differentiated thyroid cancer (DTC) after surgery. While it reduces recurrence risk in high-risk patients, its intensity should be tailored according to risk stratification. This study aimed to evaluate physicians&apos; adherence to recommendations on TSH suppression therapy in patients with DTC after surgery and/or radioiodine therapy. Design: This prospective study included patients managed at two specialized centres following total thyroidectomy for DTC. Methods: Patients on a stable levothyroxine dose for at least three months were enrolled. Data collected at the last follow-up included serum TSH, free thyroxine (FT4), free triiodothyronine (FT3), thyroglobulin, and anti-thyroglobulin antibody levels. TSH values were categorized as within target range, below target (over-suppressed), or above target (under-suppressed) according to American Thyroid Association guidelines and recurrence risk (low, intermediate, high). Results: Of 365 patients (female/male ratio: 306/59; mean age: 54.7 years for females, 56.3 years for males), only 136 (37.3%) achieved target TSH levels. TSH was under-suppressed in 86 patients (23.6%) and over-suppressed in 129 patients (35.3%). Over-suppression was most prevalent (62%) in the low-risk group. Conclusions: Adherence to guideline-recommended TSH suppression therapy in DTC remains suboptimal, with frequent over-suppression, particularly in low-risk patients. These findings highlight the need for individualized suppression strategies balancing recurrence prevention and the avoidance of iatrogenic complications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislava Medical Journal

ISSN

0006-9248

e-ISSN

1336-0345

Svazek periodika

126

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

7

Strana od-do

3651-3657

Kód UT WoS článku

001590701900001

EID výsledku v databázi Scopus

2-s2.0-105018343590